Clinical trial
A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Patients With Acromegaly and Neuroendocrine Tumours (NETs) Previously Treated With Sandostatin® LAR®
NCT02299089 is registered in ClinicalTrials.gov with Camurus AB as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Patients With Acromegaly and Neuroendocrine Tumours (NETs) Previously Treated With Sandostatin® LAR®
- Lead sponsor
- Camurus AB
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2015
- Completion date
- June 30, 2016
- Enrollment
- 12 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.